Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone vs Spironolactone in Primary Aldosteronism
NCT05814770Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of finerenone in primary aldosteronism (PA), hypertension (HTN), sponsored by Nanjing Drum-Tower Hospital. Planned start May 2023; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
primary aldosteronism (PA)hypertension (HTN)
Beyond the preview
Go deeper on NCT05814770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814770.